dain
bosworth
said
wednesday
initiated
coverage
theragenics
corp
buy
rating
12-month
price
target
28
32
dain
earnings
share
estimates
company
0.31
1997
0.55
1998
1.17
1999
theragenics
established
core
competence
manufacturing
radioactive
substance
palladium-103
producing
small
thereaseed
devices
treating
early
stage
cases
prostate
cancer
dain
said
report
theragenics
1/2
18-1/4
reuters
chicago
newsdesk
312
408-8787
